aromatase

Summary

Gene Symbol: aromatase
Description: cytochrome P450, family 19, subfamily A, polypeptide 1
Alias: ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM, aromatase, cytochrome P-450AROM, cytochrome P450 19A1, cytochrome P450, subfamily XIX (aromatization of androgens), estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Species: human

Top Publications

  1. doi Characterisation of aromatase expression in the human adipocyte cell line SGBS
    Kerry J McInnes
    Prince Henry s Institute of Medical Research, Clayton, Victoria, Australia
    Breast Cancer Res Treat 112:429-35. 2008
  2. ncbi Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Cancer Res 67:1893-7. 2007
  3. pmc Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk
    Marc T Goodman
    Cancer Epidemiology Program, Cancer Research Center of Hawaii, Honolulu, Hawaii, USA
    Endocr Relat Cancer 15:1055-60. 2008
  4. ncbi Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk
    Katie A Ashton
    Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle, Australia
    Cancer Epidemiol 34:328-37. 2010
  5. ncbi Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients
    Peter Andreas Fasching
    University Breast Center for Franconia, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany
    Breast Cancer Res Treat 112:89-98. 2008
  6. ncbi Breast cancer: a candidate gene approach across the estrogen metabolic pathway
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, Germany
    Breast Cancer Res Treat 108:137-49. 2008
  7. pmc Association study of aromatase gene (CYP19A1) in essential hypertension
    Masanori Shimodaira
    MD Program, Nihon University School of Medicine, Tokyo, Japan
    Int J Med Sci 5:29-35. 2008
  8. ncbi Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls
    Xiangyu Ma
    Department of Epidemiology, Faculty of Preventive Medicine, Third Military Medical University, Gaotanyan Street 30, Chongqing, 400038, China
    Breast Cancer Res Treat 122:495-501. 2010
  9. ncbi Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer
    Natsumi Irahara
    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Shi, Osaka 565 0871, Japan
    Cancer Lett 243:23-31. 2006
  10. doi Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts
    Ashwini L Chand
    Prince Henry s Institute, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia
    Steroids 76:741-4. 2011

Detail Information

Publications243 found, 100 shown here

  1. doi Characterisation of aromatase expression in the human adipocyte cell line SGBS
    Kerry J McInnes
    Prince Henry s Institute of Medical Research, Clayton, Victoria, Australia
    Breast Cancer Res Treat 112:429-35. 2008
    b>Aromatase is a member of the cytochrome P450 superfamily of enzymes which catalyses the rate-limiting step in the biosynthesis of estrogens...
  2. ncbi Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Cancer Res 67:1893-7. 2007
    The CYP19A1 gene encodes the enzyme aromatase, which is responsible for the final step in the biosynthesis of estrogens...
  3. pmc Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk
    Marc T Goodman
    Cancer Epidemiology Program, Cancer Research Center of Hawaii, Honolulu, Hawaii, USA
    Endocr Relat Cancer 15:1055-60. 2008
    ..The production of estrogen involves the conversion of androgens via P450 aromatase, encoded by the CYP19A1 gene...
  4. ncbi Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk
    Katie A Ashton
    Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle, Australia
    Cancer Epidemiol 34:328-37. 2010
    ..The environmental and reproductive risk factors that influence these hormones are well known, however, genetic variants involved in hormone biosynthesis and estrogen metabolism have not been well established in endometrial cancer...
  5. ncbi Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients
    Peter Andreas Fasching
    University Breast Center for Franconia, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany
    Breast Cancer Res Treat 112:89-98. 2008
    ..b>Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis...
  6. ncbi Breast cancer: a candidate gene approach across the estrogen metabolic pathway
    Christina Justenhoven
    Molecular Mechanisms of Origin and Treatment of Breast Cancer, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, Germany
    Breast Cancer Res Treat 108:137-49. 2008
    ..The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk. Therefore, future association studies should be extended to other polymorphisms and other regulatory pathways...
  7. pmc Association study of aromatase gene (CYP19A1) in essential hypertension
    Masanori Shimodaira
    MD Program, Nihon University School of Medicine, Tokyo, Japan
    Int J Med Sci 5:29-35. 2008
    As aromatase-deficient mice, which are deficient in estrogens, reportedly have reduced blood pressure, the aromatase gene (CYP19A1) is thought to be a susceptibility gene for essential hypertension (EH)...
  8. ncbi Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls
    Xiangyu Ma
    Department of Epidemiology, Faculty of Preventive Medicine, Third Military Medical University, Gaotanyan Street 30, Chongqing, 400038, China
    Breast Cancer Res Treat 122:495-501. 2010
    The association of CYP19 gene polymorphisms with breast cancer has been widely reported, but results of previous studies were somewhat contradictory and underpowered...
  9. ncbi Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer
    Natsumi Irahara
    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Shi, Osaka 565 0871, Japan
    Cancer Lett 243:23-31. 2006
    Expression of the estrogen-synthesizing genes aromatase, steroid sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type1 (17beta-HSD(1)) has been shown to be up-regulated in primary breast cancer tissue but their expression status ..
  10. doi Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts
    Ashwini L Chand
    Prince Henry s Institute, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia
    Steroids 76:741-4. 2011
    In postmenopausal breast cancers, the increase in aromatase expression observed in tumour associated adipose stromal cells is mediated via the upregulation of promoter II (PII) transcription...
  11. doi Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians
    Motoki Iwasaki
    Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo 104 0045, Japan
    Nutr Cancer 62:466-75. 2010
    We tested the hypothesis that polymorphisms in cytochrome P450c17alpha (CYP17), aromatase (CYP19), 17beta-hydroxysteroid dehydrogenase type I (17beta-HSD1) and sex hormone-binding globulin (SHBG) genes may modify the association between ..
  12. pmc Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes
    Hannah P Yang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20852, USA
    Carcinogenesis 31:827-33. 2010
    ..Associations with variants in other genes have been suggested, but findings have been inconsistent...
  13. ncbi Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women
    Shelley S Tworoger
    The Fred Hutchinson Cancer Research Center, Cancer Prevention Research Program, Seattle, Washington, USA
    Cancer Epidemiol Biomarkers Prev 13:94-101. 2004
    ..may influence sex hormone concentrations have been identified, including CYP17 (5'-untranslated region T-->C), CYP19 [intron 4 (TTTA)(n = 7-13) and a 3-bp deletion (-3)], CYP1B1 (Val(432)Leu), and COMT (Val(108/158)Met)...
  14. pmc Follicle-stimulating hormone/cAMP regulation of aromatase gene expression requires beta-catenin
    Tehnaz N Parakh
    School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
    Proc Natl Acad Sci U S A 103:12435-40. 2006
    ..of estradiol in women are controlled by follicle-stimulating hormone (FSH), which regulates transcription of the aromatase gene (CYP19A1) in ovarian granulosa cells...
  15. doi Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women
    Lina Zhang
    Departments of Breast Oncology Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China
    Breast Cancer Res Treat 114:327-38. 2009
    ..regulatory regions of ER-alpha (rs3798577) and other two estrogen-metabolizing enzyme genes CYP17 (rs743572) and CYP19 (rs10046) among 300 breast cancer cases and 390 controls in a Chinese population...
  16. pmc Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium
    Veronica Wendy Setiawan
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Cancer Epidemiol Biomarkers Prev 18:242-7. 2009
    ..Our study provides evidence that CYP19A1 genetic variation influences susceptibility to endometrial cancer, particularly among older and obese women...
  17. ncbi Organization of the human aromatase p450 (CYP19) gene
    Serdar E Bulun
    Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois 60611, USA
    Semin Reprod Med 22:5-9. 2004
    ..in general, including adipose tissue of the disease-free breast, on the other hand, maintains low levels of aromatase expression primarily via promoter I.4, which lies 73 kb upstream of the common coding region. Promoters I...
  18. ncbi EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange
    Kotha Subbaramaiah
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    J Biol Chem 283:3433-44. 2008
    Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens...
  19. ncbi Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
    E P Smith
    Department of Pediatrics, Children s Hospital Medical Center, University of Cincinnati College of Medicine, OH 45229
    N Engl J Med 331:1056-61. 1994
    ..Estrogen-receptor DNA, extracted from lymphocytes, was evaluated by analysis of single-strand-conformation polymorphisms and by direct sequencing...
  20. ncbi Multilocus analyses reveal involvement of the ESR1, ESR2, and FSHR genes in migraine
    Agustin Oterino
    University Hospital Marqués de Valdecilla Neurology, Santander, Spain
    Headache 48:1438-50. 2008
    ..Research in this field has been controversial, especially in regard to ESR1 gene findings. None of the reports have yet to approach the problem from a multigenic point of view...
  21. pmc Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women
    Hui Cai
    Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN 37203 1738, USA
    Pharmacogenet Genomics 18:657-64. 2008
    ..We investigated the associations of genetic polymorphisms in CYP19A1, a critical gene involved in estrogen synthesis, with plasma levels of sex hormones among postmenopausal Chinese women...
  22. doi Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men
    Tomoko Sonoda
    Department of Public Health, Sapporo Medical University School of Medicine, Hokkaido, Japan
    Eur J Cancer Prev 19:131-7. 2010
    ..This study examined whether the genetic polymorphisms of estrogen receptors (ESR-alpha and ESR-beta) and cytochrome P450 19A1 (CYP19A1) modified the protective effect of isoflavones against prostate cancer...
  23. doi A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro
    Hui Wang
    Shaanxi Maternal and Child Care Service Center, Xi an, People s Republic of China
    Mol Hum Reprod 17:386-91. 2011
    b>Aromatase is a key enzyme involved in estradiol and estrone biosynthesis...
  24. ncbi WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells
    Bilgin Gurates
    Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Clin Endocrinol Metab 87:4369-77. 2002
    ..SF-1) induces the expression of Müllerian inhibiting substance (MIS) and many steroidogenic genes, including aromatase P450 (P450arom)...
  25. ncbi Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations
    Clive J Petry
    Department of Paediatrics, University of Cambridge, UK
    J Steroid Biochem Mol Biol 98:199-206. 2006
    We recently reported association between a coding-region single nucleotide polymorphism (SNP50) in the aromatase gene that encodes a key enzyme in testosterone metabolism, with risk for the development of precocious pubarche and ..
  26. pmc Organization of cytochrome P450 enzymes involved in sex steroid synthesis: PROTEIN-PROTEIN INTERACTIONS IN LIPID MEMBRANES
    Slavica Praporski
    School of Chemistry, Monash University, Clayton, 3800 Victoria, Australia
    J Biol Chem 284:33224-32. 2009
    ..type steroidogenic cytochrome P450 (P450, CYP) enzymes: 17alpha-hydroxylase/17,20-lyase (P450c17, CYP17) and aromatase (P450arom, CYP19), as well as their electron donor NADPH-cytochrome P450 oxidoreductase (CPR)...
  27. pmc Higher order organization of human placental aromatase
    Debashis Ghosh
    Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
    Steroids 76:753-8. 2011
    b>Aromatase (CYP19A1) is an integral membrane enzyme that catalyzes the removal of the 19-methyl group and aromatization of the A-ring of androgens...
  28. ncbi The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women
    Ji Young Kim
    Department of Biochemistry and Molecular Biology BK21 project, School of Medicine, Kyung Hee University, Seoul, Korea
    Oncol Rep 22:487-92. 2009
    b>Aromatase encoding by the CYP19 gene catalyzes the conversion of androgens to estrogens...
  29. doi Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer
    Masao Izawa
    Division of Biosignaling, Department of Biomedical Science, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi Machi, Yonago 683 8503, Japan
    Gastric Cancer 11:103-10. 2008
    ..In the present study, we examined aromatase expression in gastric carcinoma.
  30. doi Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells
    Stefania Catalano
    Department of Pharmaco Biology, University of Calabria, Arcavacata di Rende CS 87030, Italy
    Mol Endocrinol 23:1634-45. 2009
    In situ estrogen production by aromatase conversion from androgens plays an important role in breast tumor promotion...
  31. ncbi Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis
    Jose A Riancho
    Department of Internal Medicine, Hospital U M Valdecilla, University of Cantabria, 39008 Santander, Spain
    J Clin Endocrinol Metab 92:660-5. 2007
    Osteoporosis has a significant genetic component. The aromatase-dependent conversion of androgenic precursors is the main source of estrogens in postmenopausal women.
  32. pmc A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
    Zaida Garcia-Casado
    Laboratory of Molecular Biology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain
    BMC Cancer 10:36. 2010
    b>Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC)...
  33. ncbi Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
    A Morishima
    Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA
    J Clin Endocrinol Metab 80:3689-98. 1995
    The aromatase enzyme complex catalyzes the conversion of androgens to estrogens in a wide variety of tissues, including the ovary, testis, placenta, brain, and adipose tissue...
  34. ncbi Effect of testosterone and estradiol in a man with aromatase deficiency
    C Carani
    Department of Internal Medicine, University of Modena, Italy
    N Engl J Med 337:91-5. 1997
  35. ncbi Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study
    Nancy F Woods
    Department of Family and Child Nursing, School of Nursing, University of Washington, Seattle, WA 98195 7260, USA
    Menopause 13:902-10. 2006
    ..The purpose of this study was to determine whether polymorphisms in the estrogen synthesis and metabolism pathways are associated with women's vasomotor symptom experiences during the menopausal transition...
  36. doi Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease
    Ikuko Mizuta
    Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine, 2 2 B9 Yamadaoka, Suita, Osaka, 565 0871, Japan
    Hum Genet 124:89-94. 2008
    ..Our genetic analysis suggests that CALB1 is associated with PD independently of SNCA, and that FGF20 is associated with PD synergistically with SNCA...
  37. doi Alternative 5'-untranslated first exons of the mouse Cyp19A1 (aromatase) gene
    Jenny D Y Chow
    Prince Henry s Institute, Clayton, VIC 3168, Australia
    J Steroid Biochem Mol Biol 115:115-25. 2009
    The human aromatase gene (CYP19A1) has eleven tissue-specific untranslated first exons, while only three have been described in the mouse Cyp19A1 namely brain-, ovary- and testis-specific exons 1...
  38. ncbi Polymorphisms associated with circulating sex hormone levels in postmenopausal women
    Alison M Dunning
    Cancer Research UK, Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
    J Natl Cancer Inst 96:936-45. 2004
    ..We investigated the association between levels of sex hormones and single nucleotide polymorphisms (SNPs) in genes coding for the enzymes that regulate them...
  39. ncbi Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women
    Lukas A Hefler
    Department of Obstetrics and Gynecology, Medical University Vienna, Vienna, Austria
    Cancer 101:264-9. 2004
    ..In these candidate genes, no critical combination of single-nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date...
  40. ncbi Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line
    Stefania Catalano
    Centro Sanitario and the Department of PharmacoBiology, Faculty of Pharmacy, University of Calabria, 87030 Arcavacata di Rende, Italy
    J Biol Chem 278:28668-76. 2003
    ..risk factor particularly in postmenopausal women, where estrogen production by adipose tissue through its own aromatase activity stimulates tumor progression...
  41. pmc Structural basis for androgen specificity and oestrogen synthesis in human aromatase
    Debashis Ghosh
    Structural Biology, Hauptman Woodward Medical Research Institute, 700 Ellicott Street, Buffalo, New York 14203, USA
    Nature 457:219-23. 2009
    b>Aromatase cytochrome P450 is the only enzyme in vertebrates known to catalyse the biosynthesis of all oestrogens from androgens. Aromatase inhibitors therefore constitute a frontline therapy for oestrogen-dependent breast cancer...
  42. ncbi Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis
    G D Means
    Department of Obstetrics and Gynecology, Cecil H and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas 75235 9051
    J Biol Chem 264:19385-91. 1989
    The structural gene encoding aromatase cytochrome P-450 (P-450AROM) was isolated from human genomic DNA. The gene spans at least 52 kilobases and is composed of 10 exons, the first of which is untranslated...
  43. ncbi A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism
    Luigi Gennari
    Department of Internal Medicine, University of Florence, 50139 Florence, Italy
    J Clin Endocrinol Metab 89:2803-10. 2004
    ..plays a dominant role in determining bone mineral density (BMD) in men, and inactivating mutations in the aromatase CYP19 gene have been associated with low bone mass in young males...
  44. ncbi The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer
    M Salhab
    St George s Hospital, Blackshaw Road, London, Tooting, UK
    Breast Cancer Res Treat 99:155-62. 2006
    ..The cytochrome P-450 aromatase enzyme complex is responsible for the conversion of C19 androgens to estrogens and 17-beta-hydroxysteroid ..
  45. ncbi Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer
    Natsumi Irahara
    Department of Surgical Oncology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Shi, Osaka 565 0871, Japan
    Int J Cancer 118:1915-21. 2006
    The purpose of the present study was to study the aromatase mRNA expression as well as promoter usage (I.4, I.3, PII and I...
  46. ncbi The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women
    Fariba Baghaei
    The Cardiovascular Institute, Sahlgrenska University Hospital, Goteborg, Sweden
    Obes Res 11:578-85. 2003
    ..androgens in women are associated with type 2 diabetes and are dependent on the conversion to estrogens by aromatase cytochrome P450...
  47. ncbi Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study
    Inga Peter
    Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Massachusetts Institute of Technology, Cambridge, MA, USA
    J Hypertens 23:2193-200. 2005
    ..To examine the association between variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in men and women...
  48. ncbi Polymorphisms in steroid hormone pathway genes and mammographic density
    Christopher A Haiman
    Department of Epidemiology, Harvard School of Public Health Boston, MA, USA
    Breast Cancer Res Treat 77:27-36. 2003
    ..to investigate variation in mammographic breast density, by 10 polymorphisms in eight candidate genes (CYP17, CYP19, CYP1A1, CYP1B1, COMT, UGT1A1, AR, and AIB1). Breast density was assessed using a computer-assisted technique...
  49. ncbi Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women
    C J Petry
    Department of Paediatrics, University of Cambridge, Cambridge CB2 2QQ, UK
    Hum Reprod 20:1837-43. 2005
    b>Aromatase catalyses the conversion of androgens to estrogens and thus variation in the aromatase gene could contribute to female syndromes of androgen excess, such as precocious pubarche (PP) and polycystic ovarian syndrome (PCOS).
  50. pmc Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis
    Tapan K Mukherjee
    Department of Obstetrics and Gynecology, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1740, USA
    Proc Natl Acad Sci U S A 99:4055-60. 2002
    ..whether testosterone inhibited TNFalpha-induced VCAM-1 expression via its conversion to estradiol by the enzyme aromatase in human umbilical vein endothelial cells (HUVEC)...
  51. ncbi No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome
    D Soderlund
    Research Unit in Developmental Biology, Hospital de Pediatria, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico, D F 06703, Mexico
    Hum Reprod 20:965-9. 2005
    ..Granulosa cells from follicles of women with PCOS have little, if any, aromatase (encoded by the CYP19 gene) activity; follicles contain low levels of estradiol, P450arom mRNA and aromatase ..
  52. ncbi Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes
    Colin D Clyne
    Prince Henry s Institute of Medical Research, 246 Clayton Road, Clayton VIC 3168, Australia
    J Biol Chem 277:20591-7. 2002
    Estrogen biosynthesis from C(19) steroids is catalyzed by aromatase cytochrome P450. Aromatase is expressed in breast adipose tissue through the use of a distal, cytokine-responsive promoter (promoter I.4)...
  53. ncbi A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Rm 4441, Los Angeles, CA 90089 9175, USA
    Hum Mol Genet 12:2679-92. 2003
    The CYP19 gene encodes for aromatase (P450arom), a key steroidogenic enzyme that catalyzes the final step of estrogen biosynthesis...
  54. ncbi WT1 and DAX-1 regulate SF-1-mediated human P450arom gene expression in gonadal cells
    Bilgin Gurates
    Departments of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Illinois at Chicago, 820 S Wood Street, M C 808, Chicago, IL 60612, USA
    Mol Cell Endocrinol 208:61-75. 2003
    ..b>Aromatase P450 (P450arom) is the rate-limiting enzyme for estrogen formation...
  55. ncbi CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women
    Fabiana Siqueira Ribeiro
    Departamento de Bioquimica, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Av 28 de Setembro, 87 Fundos, 4 andar, Rio de Janeiro, RJ 20551 013, Brazil
    Toxicol Lett 164:90-5. 2006
    ..The CYP19 gene encodes the enzyme aromatase, which catalyzes the conversion of androgens into estrogens...
  56. ncbi CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study
    Bharat Thyagarajan
    School of Public Health, Division of Epidemiology, University of Minnesota, Minneapolis, MN 55454, USA
    Cancer Lett 207:183-9. 2004
    ..breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene...
  57. ncbi Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: Sex specificities
    Marie Noelle Dieudonne
    Service de Biochimie et de Biologie Moléculaire, UPRES EA 2493, Faculte de Medecine Paris Ile de France Ouest, Universite Versailles St Quentin, Centre Hospitalier de Poissy, 78303 Poissy Cedex, France
    J Steroid Biochem Mol Biol 99:189-96. 2006
    ..dehydrogenase (HSD1), the enzyme responsible for the conversion of cortisone into cortisol and the P450 aromatase, the enzyme catalysing androgens aromatization into estrogens, are both expressed in human adipose tissue...
  58. pmc Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females
    Yan Guo
    Key Laboratory of Biomedical Information Engineering, Ministry of Education and Institute of Molecular Genetics, School of Life Science and Technology, Xi an Jiaotong University, Xi an 710049, People s Republic of China
    Hum Mol Genet 15:2401-8. 2006
    ..Our study aimed to identify whether the CYP17 and CYP19, the two key genes involved in the biosynthesis of estrogen, are associated with AAM variation in 1048 females ..
  59. pmc CYP19 haplotypes increase risk for Alzheimer's disease
    R Huang
    J Med Genet 43:e42. 2006
    Cytochrome P450 aromatase, an enzyme that catalyses the conversion of androgens to oestrogen, is expressed at high levels in the gonads and in the brain...
  60. pmc Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study
    Qiuyin Cai
    Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, B 2104 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232 2400, USA
    Cancer Epidemiol Biomarkers Prev 17:27-32. 2008
    Estrogens play a central role in the etiology of breast cancer. The CYP19A1 gene encodes aromatase, a key enzyme in the biosynthesis of estrogens...
  61. ncbi A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
    Ramon Colomer
    M D Anderson Cancer Center España, Madrid, Spain
    Clin Cancer Res 14:811-6. 2008
    To evaluate the efficacy of treatment with the aromatase inhibitor letrozole in breast cancer patients segregated with respect to DNA polymorphisms of the aromatase gene CYP19.
  62. ncbi In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
    Barbara E Licznerska
    Institution of Clinical and Experimental Medicine, Division of Cell Biology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Breast Cancer Res Treat 112:15-23. 2008
    ....
  63. doi Regulation of breast cancer-associated aromatase promoters
    Dong Chen
    Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Northwestern University, 303 E Superior Street, Chicago, IL 60611, USA
    Cancer Lett 273:15-27. 2009
    By converting androstenedione to estrone, or testosterone to estradiol, aromatase is a key enzyme in estrogen biosynthesis...
  64. ncbi Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues
    G D Means
    Cecil H and Ida Green Center for Reproductive Biological Sciences, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235 9051
    Mol Endocrinol 5:2005-13. 1991
    The formation of estrogens from C19 steroids is catalyzed by a specific form of cytochrome P450, aromatase cytochrome P450 (P450AROM; the product of the CYP19 gene)...
  65. pmc The alternative noncoding exons 1 of aromatase (Cyp19) gene modulate gene expression in a posttranscriptional manner
    Hanzhou Wang
    Department of Molecular Medicine, Institute of Biotechnology, 15355 Lambda Drive, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245, USA
    Endocrinology 150:3301-7. 2009
    b>Aromatase (Cyp19) is a key enzyme in estrogen biosynthesis and an important target in endocrine therapy for estrogen receptor (ER)-positive postmenopausal breast cancer...
  66. pmc Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries
    Y Ito
    Cecil H and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas 75235
    Proc Natl Acad Sci U S A 90:11673-7. 1993
    We identified two mutations in the CYP19 gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries...
  67. ncbi Novel exon 1 of the aromatase gene specific for aromatase transcripts in human brain
    S Honda
    Division of Molecular Genetics, Fujita Health University, Aichi, Japan
    Biochem Biophys Res Commun 198:1153-60. 1994
    b>Aromatase in the brain is supposed to participate in sexual differentiation of the brain...
  68. ncbi Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue
    M S Mahendroo
    Cecil H and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas 75235
    J Biol Chem 268:19463-70. 1993
    Estrogen biosynthesis is catalyzed by a microsomal enzyme, aromatase cytochrome P450 (P450arom; the product of the CYP19 gene). The human CYP19 gene comprises nine coding exons, II-X...
  69. ncbi Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants
    Reposo Ramirez-Lorca
    Departamento de Genomica Estructural, Neocodex, Parque Tecnológico Isla de la Cartuja, Sevilla, Spain
    Hypertension 50:884-90. 2007
    ..A key enzyme in determining estrogen levels is aromatase cytochrome P450...
  70. pmc Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels
    Inga Peter
    Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    J Clin Endocrinol Metab 93:2779-85. 2008
    ..associations between variations in genes encoding estrogen receptors alpha (ESR1) and beta (ESR2), and enzyme aromatase (CYP19A1), which regulates the estrogen to testosterone ratio, and cardiovascular phenotypes in the Framingham ..
  71. ncbi A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives
    Zhen Hu
    Breast Cancer Institute, Cancer Hospital, Department of Oncology, Shanghai Medical College, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
    J Cancer Res Clin Oncol 133:969-78. 2007
    ..The genotypes of estrogen receptor alpha (ERalpha), aromatase (CYP19), and catechol-O-methyltransferase (COMT) genes were analyzed by direct DNA-sequencing...
  72. ncbi Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women
    Ruth Warren
    Department of Radiology, University of Cambridge, United Kingdom
    Cancer Epidemiol Biomarkers Prev 15:1502-8. 2006
    ..globulin (SHBG), androstenedione, 17-OH-progesterone, estrone, and estrone sulfate] and 15 SNPs in the CYP17, CYP19, EDH17B2, SHBG, COMT, and CYP1B1 genes were studied...
  73. ncbi Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study
    D Song
    First Teaching Hospital of Jilin University, Changchun, China
    J Steroid Biochem Mol Biol 101:136-44. 2006
    ..The steroidogenic enzymes involved in E2 formation are aromatase which transforms testosterone into E2 and androstenedione into estrone (E1) and reductive 17beta-hydroxysteroid ..
  74. ncbi Polymorphic variation in CYP19 and the risk of breast cancer
    S W Baxter
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Institute, Locked Bag No 1 A Beckett St, Victoria 8006, Australia
    Carcinogenesis 22:347-9. 2001
    The production of estrogen from androgen via the estrogen biosynthesis pathway is catalyzed by aromatase P450 (cyp19)...
  75. pmc A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
    Janet E Olson
    Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Breast Cancer Res Treat 102:237-47. 2007
    ..Androgens are converted to estrogens by the aromatase enzyme, which is encoded by the CYP19 gene...
  76. ncbi 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production
    Takashi Suzuki
    Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
    Int J Cancer 120:285-91. 2007
    ..was positively associated with 5alpha-reductase type 1 (5alphaRed1), and negatively correlated with aromatase. We then examined clinical significance of AR and 5alphaRed1 status in 115 breast carcinoma tissues by ..
  77. ncbi Genetic polymorphisms of the CYP19A1 gene and breast cancer survival
    Ji Rong Long
    Department of Medicine, Center for Epidemiologic Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2587, USA
    Cancer Epidemiol Biomarkers Prev 15:2115-22. 2006
    The CYP19A1 protein (aromatase) plays a critical role in estrogen biosynthesis and thus may be related to the progression of breast cancer...
  78. ncbi Herbicide atrazine activates SF-1 by direct affinity and concomitant co-activators recruitments to induce aromatase expression via promoter II
    WuQiang Fan
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Maidashi 3 1 1, Higashi ku, Fukuoka 812 8582, Japan
    Biochem Biophys Res Commun 355:1012-8. 2007
    ..We recently reported that atrazine induces human aromatase gene expression via promoter II (ArPII) in a steroidogenic factor 1 (SF-1)-dependent manner...
  79. pmc Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells
    Stefania Catalano
    Department of Pharmaco Biology, University of Calabria, 87030 Arcavacata di Rende Cs, Italy
    J Biol Chem 285:5581-93. 2010
    ..Recently, FXR was identified as a negative modulator of the androgen-estrogen-converting aromatase enzyme in human breast cancer cells...
  80. ncbi Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue
    Shiuan Chen
    Department of Surgical Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91006, USA
    J Steroid Biochem Mol Biol 95:17-23. 2005
    ..3 and PII are the two major exon Is present in aromatase mRNAs isolated from breast tumors. These results suggest that promoters I...
  81. ncbi Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood
    P E Mullis
    Division of Paediatric Endocrinology, University Children s Hospital, Bern, Switzerland
    J Clin Endocrinol Metab 82:1739-45. 1997
    ..This mutation ignores the splice site and a stop codon 3 bp downstream occurs. Aromatase deficiency was already suspected because of the marked virilization occurring prepartum in the mother, and the ..
  82. ncbi Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15
    S A Chen
    Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA 91010
    DNA 7:27-38. 1988
    The amino acid sequence of human placental aromatase was determined in part (about 40%) by microsequencing methods...
  83. ncbi Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta
    M S Mahendroo
    Cecil H and Ida Green Center for Reproductive Biology Sciences, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235 9051
    J Biol Chem 266:11276-81. 1991
    The biosynthesis of estrogens from androgens is catalyzed by a enzyme of the endoplasmic reticulum termed aromatase cytochrome P-450 (P-450AROM)...
  84. ncbi Novel endocrine therapies in breast cancer
    J G Klijn
    Department of Medical Oncology, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek, The Netherlands
    Acta Oncol 35:30-7. 1996
    ..in the endocrine therapy of breast cancer are application of new antiestrogens, antiprogestins, new potent aromatase inhibitors, analogues of luteinizing hormone-releasing hormone (LHRH-A) and somatostatin, inhibitors of ..
  85. ncbi RU-486 inhibits rat gonadal steroidogenesis
    P E Sanchez
    Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, Maryland
    Horm Metab Res 21:369-71. 1989
    ..Testicular 17-hydroxylase and aromatase activity decreased in RU-486 treated animals whereas 17,20-desmolase, 3 beta-hydroxysteroid dehydrogenase and 17-..
  86. ncbi Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma
    H Templ
    , Wien, Austria
    Horm Metab Res 20:522-4. 1988
    Microsomal aromatase activity was assayed in testicular tumour tissue from one patient with choriocarcinoma and two patients with embryonal carcinoma...
  87. ncbi Endocrine, paracrine and autocrine control of follicular development
    P Franchimont
    Radioimmunoassay Laboratory, , Belgium
    Horm Metab Res 20:193-203. 1988
    ..results from the action of several endocrine, paracrine and autocrine mechanisms which synergistically inhibit aromatase activity. The subsequent lack of estrogens reduces granulosa cell multiplication...
  88. pmc Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1
    Z J Wang
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Proc Natl Acad Sci U S A 98:7988-93. 2001
    ..Expression of the aromatase (Cyp19) gene, which encodes the enzyme that converts testosterone to estradiol, was increased significantly in ..
  89. ncbi Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer?
    E Bajetta
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 82:417-22. 1996
    ..The clinical results obtained with aminoglutethimide, and later with formestane, have established aromatase inhibition as one of the major therapeutic options in hormone-dependent advanced disease...
  90. ncbi Formestane as treatment of advanced breast cancer in elderly women
    N Zilembo
    Medical Oncology Division B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 80:433-7. 1994
    ..was to evaluate the endocrinologic and clinical activity of formestane (4-hydroxyandrostenedione), a selective aromatase inhibitor, in elderly patients with advanced breast cancer...
  91. ncbi Theoretical investigations on the role of steroid-skeleton C4 = C5 unsaturation in competitive aromatase inhibition
    M Bohl
    Akademie der Wissenschaften der DDR, , Jena
    Z Naturforsch C 44:217-25. 1989
    ..to give indications about the role of the C4 = C5 double bond in competitive inhibition of human placental aromatase and about sterical requirements in steroid-aromatase interactions...
  92. ncbi Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients
    P F Trunet
    Department of Research, Pharmaceuticals Division, Ciba-Geigy Limited, Basel, Switzerland
    Acta Oncol 35:15-8. 1996
    Letrozole is a new orally, active, potent, and highly specific non-steroidal aromatase inhibitor. Letrozole is about 200 and 10000 times as potent as aminoglutethimide (AG) in vitro and in vivo, respectively...
  93. ncbi Aromatase inhibition for breast cancer treatment
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 35:38-43. 1996
    While the first generation aromatase inhibitor aminoglutethimide and second- and third generation inhibitors like formestane and fadrozole all have been found to inhibit in vivo aromatization by 85-93%, the novel aromatase inhibitors ..
  94. pmc The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
    P E Lønning
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 63:789-93. 1991
    The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer...
  95. ncbi Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer
    S Barni
    Division of Oncological Radiotherapy, Ospedale S. Gerardo, Monza (Milan, Italy
    Tumori 84:45-7. 1998
    AIMS AND BACKGROUND: It is known that the aromatase inhibitors may act by decreasing estrogen levels. Moreover, it is known that estrogens may stimulate the release of prolactin (PRL), which is a growth factor for breast cancer...
  96. ncbi New endocrine drugs for treatment of advanced breast cancer
    P E Lønning
    Department of Medicine, Royal Marsden Hospital, Sutton, England
    Acta Oncol 29:379-86. 1990
    Current status of endocrine treatment for breast cancer is reviewed. Several new aromatase inhibitors as well as antiestrogens are being introduced for clinical trials...
  97. ncbi Endocrine treatment of advanced breast cancer
    M Dowsett
    Royal Marsden Hospital, London, England
    Acta Oncol 35:68-72. 1996
    ..New antioestrogens with reduced or no agonist activity, and potent, more specific, aromatase inhibitors are now reaching the clinic...
  98. ncbi Proper sequence of endocrine therapies in advanced breast cancer
    C Rose
    Department of Oncology R, Odense University Hospital
    Acta Oncol 35:44-9. 1996
    ..New selective aromatase inhibitors (AI) are now in clinical use. The first commercially available of these inhibitors is LENTARON...
  99. ncbi Aromatase inhibitors: past, present and future
    G Seralini
    Laboratory of Biochemistry and Molecular Biology, EA2608, IBBA, University of Caen, Esplanade de la Paix, 14032 Cedex, Caen, France
    Mol Cell Endocrinol 178:117-31. 2001
    ..This ratio is controlled in vertebrates by aromatase; its gene expression can be inhibited in different ways, and this is crucial for the treatment of estrogen-..
  100. ncbi Anti-tumor effects of letrozole
    W R Miller
    Breast Unit Research Group, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK
    Cancer Invest 20:15-21. 2002
    ..e., the conversion of androgens to estrogens by the aromatase enzyme. Recently, a new generation of aromatase inhibitors has been developed...

Research Grants127 found, 100 shown here

  1. Hormonal regulation of the brain microenvironment and its contribution to brain m
    Diana M Cittelly; Fiscal Year: 2013
    ..Steroid hormones produced by gonads or adrenals cross the blood brain barrier, and are also produced locally by aromatase expressed in neurons and astrocytes...
  2. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2010
    ..e., tumors that are resistant to mainstay breast cancer therapies such as tamoxifen and aromatase inhibitors) breast cancer xenograft models...
  3. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2013
    ..e., tumors that are resistant to mainstay breast cancer therapies such as tamoxifen and aromatase inhibitors) breast cancer xenograft models...
  4. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2010
    ..and limiting toxicity of chemo-preventive agents which include selective estrogen receptor antagonists, aromatase inhibitors, retinoids, COX-2 inhibitors and metformin...
  5. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2012
    ..and limiting toxicity of chemo-preventive agents which include selective estrogen receptor antagonists, aromatase inhibitors, retinoids, COX-2 inhibitors and metformin...
  6. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2013
    ..and limiting toxicity of chemo-preventive agents which include selective estrogen receptor antagonists, aromatase inhibitors, retinoids, COX-2 inhibitors and metformin...
  7. Mechanisms of Breast Tumor Cell Growth, Motility, and Antiestrogen Response
    Amy H Bouton; Fiscal Year: 2010
    ..with hormonal therapies designed to inhibit receptor function (antiestrogens) or block production of estrogens (aromatase inhibitors)...
  8. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..Recently, alternative endocrine therapies, such as aromatase inhibitors (AI), are found to be more effective in estrogen receptor positive, post-menopausal women with breast ..
  9. Mechanisms of Breast Tumor Cell Growth, Motility, and Antiestrogen Response
    Amy H Bouton; Fiscal Year: 2013
    ..with hormonal therapies designed to inhibit receptor function (antiestrogens) or block production of estrogens (aromatase inhibitors)...
  10. Optic Nerve Aging and Glaucoma
    Thasarat Vajaranant; Fiscal Year: 2013
    ..This training and line of research will provide a foundation for future studies investigating the effects of aromatase inhibitors, selective estrogen receptor modulators and other anti- estrogen treatments on the optic nerve...
  11. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John A Katzenellenbogen; Fiscal Year: 2010
    ..cancer is well recognized, as is the effectiveness of hormonal agents such as the antiestrogen tamoxifen or aromatase inhibitors such as letrozole for treating certain cancers...
  12. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2013
    ..ER (designated ER+), signifying that they MAY respond favorably to endocrine therapy with tamoxifen or aromatase inhibitors...
  13. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2010
    ..ER (designated ER+), signifying that they MAY respond favorably to endocrine therapy with tamoxifen or aromatase inhibitors...
  14. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2010
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  15. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2011
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  16. Second line breast cancer therapy through a novel Phytoantiestrogen
    SYREETA LATATIA TILGHMAN; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Although aromatase inhibitors, such as letrozole, are the standard endocrine therapy of choice for post-menopausal women with early-stage metastatic estrogen-dependent breast cancer, the major ..
  17. CYP19A1 gene and Pharmacogenetics of Response
    REINA C VILLAREAL; Fiscal Year: 2013
    ..Estrogen in males is mainly derived from the conversion of testosterone to estradiol by the enzyme aromatase. Polymorphisms of the aromatase gene (CYP19A1) have been reported to result in variable enzyme activity ..
  18. Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
    Steven M Kawut; Fiscal Year: 2013
    ..variation in estrogen receptor βwas associated with the occurrence of HPS , and 3) genetic variation in aromatase was associated with both higher plasma estradiol (E2) levels and a higher risk of PPHTN...
  19. The new biology of estrogen action in aromatase resistance breast cancer cells
    JOAN SUEDEE LEWIS WAMBI; Fiscal Year: 2010
    ..PA) and I am submitting a K01 application to study the new biology of estrogen and fulvestrant action in aromatase inhibitor resistant breast cancer cells...
  20. Nsaid Effects on Clinical and Imaging Breast Biomarkers
    PATRICIA ANN THOMPSON; Fiscal Year: 2013
    ..b>Aromatase inhibitors (AI) are recommended as first-line adjuvant therapy for hormone responsive tumors in postmenopausal ..
  21. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2013
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  22. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2012
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  23. Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
    Linda Susan Taichman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) are routinely prescribed as adjuvant hormonal therapy for postmenopausal women with hormone receptor positive breast cancer...
  24. Action of RB Pathway in Breast Cancer Therapy
    Erik Knudsen; Fiscal Year: 2010
    ..g. tamoxifen) or through ER ligand depletion strategies (e.g. aromatase inhibitors)...
  25. Action of RB Pathway in Breast Cancer Therapy
    Erik Knudsen; Fiscal Year: 2013
    ..g. tamoxifen) or through ER ligand depletion strategies (e.g. aromatase inhibitors)...
  26. Action of RB Pathway in Breast Cancer Therapy
    Erik Knudsen; Fiscal Year: 2013
    ..g. tamoxifen) or through ER ligand depletion strategies (e.g. aromatase inhibitors)...
  27. Development of Breast Cancer Risk Model Based on Estrogen Metabolomics
    Richard J Santen; Fiscal Year: 2013
    ..We anticipate reducing the number of women needed to be treated to prevent one breast cancer from 50 to 13 with tamoxifen and to 5.with aromatase inhibitors.
  28. Role of pharmacogenetics on exemestane metabolism and toxicity
    Philip Lazarus; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) are widely used as adjuvant treatment for estrogen-receptor positive breast cancer in post-menopausal women...
  29. Targeting endocrine resistant breast cancer with anacardic acid
    David Schultz; Fiscal Year: 2013
    ..g., tamoxifen (TAM)) and aromatase inhibitors (AI, e.g. letrozole) against which tumor cells become resistant...
  30. Estrogen Deprivation and Aromatase Inhibitor associated Arthralgia
    Jun J Mao; Fiscal Year: 2013
    DESCRIPTION (provided by Investigator): This application entitled, "Estrogen deprivation and Aromatase Inhibitor associated Arthralgia," seeks to apply pharmacogenetic epidemiology, appropriate biomarkers, and validated patient-reported ..
  31. Genetic Predictors of Anti-Estrogen Clinical Activity in Breast Cancer Patients
    James Michael Rae; Fiscal Year: 2013
    ..therapies including the Selective Estrogen Receptor Modulator (SERM) tamoxifen, and the 3rd generation aromatase inhibitors (AI) including anastrozole, letrozole, and exemestane have clearly played a substantial role in ..
  32. Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors
    Song Yao; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) have been rapidly replacing tamoxifen (TAM) as first-line adjuvant hormonal therapy for postmenopausal women diagnosed with hormone receptor (HR)-positive, early-stage ..
  33. RCT of exercise on aromatase inhibitor side effects in breast cancer survivors
    Melinda L Irwin; Fiscal Year: 2010
    ..the standard adjuvant hormonal therapy for women with early- stage, hormone receptor-positive breast cancer, the aromatase inhibitors (AI's) have rapidly supplanted tamoxifen as the hormonal therapy of choice...
  34. Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors
    Song Yao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) have been rapidly replacing tamoxifen (TAM) as first-line adjuvant hormonal therapy for postmenopausal women diagnosed with hormone receptor (HR)-positive, early-stage ..
  35. Targeting the Obesity-Inflammation-COX-Aromatase Axis to Lower Breast Cancer Risk
    ANDREW JESS DANNENBERG; Fiscal Year: 2011
    ..from adipose tissue, since adipose tissue is the primary site of action of the estrogen-synthesizing enzyme aromatase post climacteric...
  36. Brain aromatase availability in steroid users: PET studies with [11C]vorozole
    Thomas B Hildebrandt; Fiscal Year: 2013
    ..By studying AAS intoxication in relation to aromatase availability, we will be able to understand functional relationships between AAS metabolism and the core ..
  37. Brain aromatase availability in steroid users: PET studies with [11C]vorozole
    Thomas B Hildebrandt; Fiscal Year: 2013
    ..By studying AAS intoxication in relation to aromatase availability, we will be able to understand functional relationships between AAS metabolism and the core ..
  38. Targeting the Obesity-Inflammation-COX-Aromatase Axis to Lower Breast Cancer Risk
    ANDREW JESS DANNENBERG; Fiscal Year: 2013
    ..from adipose tissue, since adipose tissue is the primary site of action of the estrogen-synthesizing enzyme aromatase post climacteric...
  39. Medications Development for the Pregnant Opiate Addict
    Mahmoud S Ahmed; Fiscal Year: 2010
    ..The activity of aromatase and P-gp are affected by placental genotype and gestational age...
  40. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy L Keating; Fiscal Year: 2010
    ..Recently, randomized controlled trials identifying substantial benefits of aromatase inhibitors for early- stage cancers have led to national recommendations that every postmenopausal woman with an ..
  41. Epigenetic Regulation of Breast Cancer Progression by the Proto-oncogene PELP1
    MONICA MANN; Fiscal Year: 2013
    ..Endocrine therapies using tamoxifen and aromatase inhibitors substantially improve disease- free survival, however, initial or acquired resistance frequently ..
  42. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..to combine three chemotherapeutic strategies currently used in the clinic: (a) hormonal therapy (tamoxifen and aromatase inhibitors), (b) targeted therapy (herceptin), and (c) standard chemotherapy (doxorubicin and taxol)...
  43. A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
    Suzanne Aw Fuqua; Fiscal Year: 2011
    ..tumors re- gress but then regrow, suggesting that the mutation also confers resistance to therapies such as aromatase inhibitors (AIs)...
  44. A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
    Suzanne Aw Fuqua; Fiscal Year: 2012
    ..tumors re- gress but then regrow, suggesting that the mutation also confers resistance to therapies such as aromatase inhibitors (AIs)...
  45. A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
    JOYCE MARIE contact SLINGERLAND; Fiscal Year: 2010
    ..receptor 1 (ER) is expressed in 70% of new breast cancers but de novo and acquired resistance to tamoxifen or aromatase inhibitors (AI) limit their efficacy...
  46. The role of the mTOR signaling pathway in ER-positive breast cancer
    MARINA KAUFMAN HOLZ; Fiscal Year: 2013
    ..ER-positive breast cancers can be targeted therapeutically by antiestrogens (such as tamoxifen) or aromatase inhibitors (AIs)...
  47. Cognitive Functioning After Breast Cancer Treatment
    Patricia A Ganz; Fiscal Year: 2010
    ..surgery, radiation, chemotherapy) and who are about to initiate adjuvant endocrine therapy (with tamoxifen or aromatase inhibitors)...
  48. LRH-1 Antagonism: Impact on Estrogen-dependent Breast Cancer
    Marcia I Dawson; Fiscal Year: 2013
    ..In the postmenopausal cancerous breast, expression of the enzyme synthesizing estrogen (aromatase) becomes elevated, as do estrogen and the estrogen nuclear receptor (ER)...
  49. Regulation of miRNA in breast cancer
    Carolyn M Klinge; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Aromatase inhibitor therapy is not useful for all ER1 positive breast cancer patients and the selective estrogen receptor ..
  50. Acupuncture and aromatase inhibitor ralated arthralgia
    Jun J Mao; Fiscal Year: 2010
    ..joint pain, is emerging as a major source of symptom burden in postmenopausal breast cancer survivors receiving Aromatase Inhibitors (AIs) as adjuvant therapy...
  51. MEK5-Erk5 in breast cancer resistance
    MATTHEW EDWARD BUROW; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: While endocrine therapies, such as the anti-estrogen tamoxifen and the aromatase inhibitors, are important tools in the treatment of ER(+) breast carcinoma in the adjuvant and metastatic ..
  52. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase
    Lisa Gallicchio; Fiscal Year: 2010
    b>Aromatase inhibitors, which suppress the production of estrogens by binding to the aromatase enzyme, have become the hormonal adjuvant treatment of choice for postmenopausal breast cancer...
  53. PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer
    Debra Tonetti; Fiscal Year: 2010
    ..In the past few years it was demonstrated that aromatase inhibitors are superior to TAM as adjuvant therapy in the postmenopausal patient population...
  54. The Mechanism of BRCA1 in Tumor Suppression
    Yanfen Hu; Fiscal Year: 2010
    ..preliminary data lead us to the hypothesis that BRCA1 may negatively regulate the tissue-specific expression of aromatase, a rate-limiting enzyme in estrogen biosynthesis and a key player in breast cancer development...
  55. 18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
    Stephen Chia; Fiscal Year: 2010
    ..is not curable however, and virtually all patients will eventually develop resistance to both tamoxifen and the aromatase inhibitors...
  56. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  57. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2002
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  58. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2004
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  59. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2002
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  60. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2003
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  61. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2001
    A number of studies have shown that the levels of aromatase are higher in breast tumors compared to normal tissue, indicating that the in situ aromatase/breast estrogen may play a role in breast cancer...
  62. The new biology of estrogen action in aromatase resistance breast cancer cells
    Joan Lewis Wambi; Fiscal Year: 2007
    ..PA) and I am submitting a K01 application to study the new biology of estrogen and fulvestrant action in aromatase inhibitor resistant breast cancer cells...
  63. The new biology of estrogen action in aromatase resistance breast cancer cells
    Joan Lewis Wambi; Fiscal Year: 2009
    ..PA) and I am submitting a K01 application to study the new biology of estrogen and fulvestrant action in aromatase inhibitor resistant breast cancer cells...
  64. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2007
    ..Used in postmenopausal women, aromatase inhibitors (AI) block the peripheral conversion of androgens to estrogen, effectively lowering the estradiol ..
  65. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2009
    ..Used in postmenopausal women, aromatase inhibitors (AI) block the peripheral conversion of androgens to estrogen, effectively lowering the estradiol ..
  66. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2009
    ..Recently, alternative endocrine therapies, such as aromatase inhibitors (AI), are found to be more effective in estrogen receptor positive, post-menopausal women with breast ..
  67. Endocrine resistance in breast cancer
    Robert Clarke; Fiscal Year: 2009
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  68. AROMATASE AND BREAST CANCER
    Shiuan Chen; Fiscal Year: 2000
    b>Aromatase converts androgen to estrogen. Aromatase is expressed at a higher level in breast cancer tissue than in benign tissue...
  69. AROMATASE AND BREAST CANCER
    Shiuan Chen; Fiscal Year: 2002
    b>Aromatase converts androgen to estrogen. Aromatase is expressed at a higher level in breast cancer tissue than in benign tissue...
  70. AROMATASE AND BREAST CANCER
    Shiuan Chen; Fiscal Year: 2004
    b>Aromatase converts androgen to estrogen. Aromatase is expressed at a higher level in breast cancer tissue than in benign tissue...
  71. AROMATASE AND BREAST CANCER
    Shiuan Chen; Fiscal Year: 2001
    b>Aromatase converts androgen to estrogen. Aromatase is expressed at a higher level in breast cancer tissue than in benign tissue...
  72. AROMATASE AND BREAST CANCER
    Shiuan Chen; Fiscal Year: 2003
    b>Aromatase converts androgen to estrogen. Aromatase is expressed at a higher level in breast cancer tissue than in benign tissue...
  73. Treatment effects on hormones in the breast
    Robert Chatterton; Fiscal Year: 2004
    ..The effects of tamoxifen and aromatase inhibitors on estrogen-induced proteins cathepsin D and trefoil family factor-1 (TFF1) will be determined in ..
  74. Treatment effects on hormones in the breast
    Robert Chatterton; Fiscal Year: 2005
    ..The effects of tamoxifen and aromatase inhibitors on estrogen-induced proteins cathepsin D and trefoil family factor-1 (TFF1) will be determined in ..
  75. RCT of exercise on aromatase inhibitor side effects in breast cancer survivors
    Melinda Irwin; Fiscal Year: 2009
    ..the standard adjuvant hormonal therapy for women with early- stage, hormone receptor-positive breast cancer, the aromatase inhibitors (AI's) have rapidly supplanted tamoxifen as the hormonal therapy of choice...
  76. Aromatase Inhibitor in Males with Adrenal Hyperplasia
    Kyriakie Sarafoglou; Fiscal Year: 2004
    ..objective is to treat males who have congenital adrenal hyperplasia (CAH) and decreased spermatogenesis with an aromatase inhibitor in order to investigate its effects on hormonal parameters and spermatogenesis...
  77. Aromatase Inhibitor in Males with Adrenal Hyperplasia
    Kyriakie Sarafoglou; Fiscal Year: 2006
    ..objective is to treat males who have congenital adrenal hyperplasia (CAH) and decreased spermatogenesis with an aromatase inhibitor in order to investigate its effects on hormonal parameters and spermatogenesis...
  78. A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
    Joyce Slingerland; Fiscal Year: 2009
    ..receptor 1 (ER) is expressed in 70% of new breast cancers but de novo and acquired resistance to tamoxifen or aromatase inhibitors (AI) limit their efficacy...
  79. Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients
    Dawn Hershman; Fiscal Year: 2012
    Third generation aromatase inhibitors have been shown to be superior to tamoxifen in improving disease free survival, decreasing distant and local recurrence rates and decreasing incidence of contra-lateral breast cancer in women with ..
  80. MECHANISMS OF INFERTILITY IN ENDOMETRIOSIS
    Serdar Bulun; Fiscal Year: 2000
    ..Our preliminary results are indicative that the aberrant expression of aromatase and cyclo-oxygenase (COX)-2 and the deficiency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD-2) in ..
  81. MECHANISMS OF INFERTILITY IN ENDOMETRIOSIS
    Serdar Bulun; Fiscal Year: 2001
    ..Our preliminary results are indicative that the aberrant expression of aromatase and cyclo-oxygenase (COX)-2 and the deficiency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD-2) in ..
  82. MECHANISMS OF INFERTILITY IN ENDOMETRIOSIS
    Serdar Bulun; Fiscal Year: 2002
    ..Our preliminary results are indicative that the aberrant expression of aromatase and cyclo-oxygenase (COX)-2 and the deficiency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD-2) in ..
  83. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2003
    ..The clinical emphasis will be on 2 types of medications - selective estrogen receptor modulators (SERMS) and aromatase inhibitors...
  84. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2004
    ..The clinical emphasis will be on 2 types of medications - selective estrogen receptor modulators (SERMS) and aromatase inhibitors...
  85. BIOCHEMICAL PROBES OF THE ACTIVE SITE OF AROMATASE
    ROBERT BRUEGGEMEIER; Fiscal Year: 1993
    ..in this competing renewal application will continue and extend investigations on the utilization of selected aromatase inhibitors as biochemical tools in studying the active site of aromatase. Investigations by the P.I...
  86. BIOCHEMICAL PROBES OF THE ACTIVE SITE OF AROMATASE
    ROBERT BRUEGGEMEIER; Fiscal Year: 1991
    ..in this competing renewal application will continue and extend investigations on the utilization of selected aromatase inhibitors as biochemical tools in studying the active site of aromatase. Investigations by the P.I...
  87. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2005
    ..The clinical emphasis will be on 2 types of medications - selective estrogen receptor modulators (SERMS) and aromatase inhibitors...
  88. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
    ..The clinical emphasis will be on 2 types of medications - selective estrogen receptor modulators (SERMS) and aromatase inhibitors...
  89. Association of breast cancer and its therapies with fracture
    Joan Neuner; Fiscal Year: 2009
    ..Finally, advances in adjuvant hormonal therapy with the introduction of aromatase inhibitors (AIs) suggest that osteoporosis will become a greater problem in the future...
  90. A Novel Long-Lived 41Ca Marker To Assess Bone Turnover For Breast Cancer Patients
    Susanta Hui; Fiscal Year: 2009
    ..b>Aromatase inhibitor (AI) is very succesful as an adjuvant therapy in estrogen positive postmenopausal women to prevent ..
  91. A Novel Long-Lived 41Ca Marker To Assess Bone Turnover For Breast Cancer Patients
    Susanta Hui; Fiscal Year: 2007
    ..b>Aromatase inhibitor (AI) is very succesful as an adjuvant therapy in estrogen positive postmenopausal women to prevent ..
  92. Acupuncture and aromatase inhibitor ralated arthralgia
    Jun Mao; Fiscal Year: 2009
    ..joint pain, is emerging as a major source of symptom burden in postmenopausal breast cancer survivors receiving Aromatase Inhibitors (AIs) as adjuvant therapy...
  93. MECHANISMS OF ESTROGEN BIOSYNTHESIS IN ENDOMETRIOSIS
    Serdar Bulun; Fiscal Year: 2002
    ..The findings of our preliminary studies include (i) significant levels of aromatase P450 (P450arom) mRNA, protein and activity in stromal cells of endometriotic tissue but not in eutopic ..